Evidence map›Paper›PMID 42257649›Full record

ArticleJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases2026

Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.

Marie-Eva Pickering, Christian Heiss, Véronique Morel, Gisèle Pickering, Marion Couderc, Sylvain Mathieu, Sandrine Malochet-Guinamand, Julie Durif, Vincent Sapin, Bruno Pereira and 2 more

Abstract read
In one paragraph

Article in Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marie-Eva PickeringRheumatology Department, CHU Clermont-Ferrand.ORCID 0000-0001-6750-2038
Christian HeissDiscipline of Clinical Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford.
Véronique MorelPlatform of Clinical Investigation Department, University Hospital Clermont-Ferrand, Inserm; Neurodol Inserm, Université Clermont Auvergne.
Gisèle PickeringPlatform of Clinical Investigation Department, University Hospital Clermont-Ferrand, Inserm; Neurodol Inserm, Université Clermont Auvergne.
Marion CoudercRheumatology Department, CHU Clermont-Ferrand.
Sylvain MathieuRheumatology Department, CHU Clermont-Ferrand.
Sandrine Malochet-GuinamandRheumatology Department, CHU Clermont-Ferrand.
Julie DurifService de Biochimie et de Génétique Moléculaire, Centre de Biologie, CHU de Clermont-Ferrand.
Vincent SapinService de Biochimie et de Génétique Moléculaire, Centre de Biologie, CHU de Clermont-Ferrand.
Bruno PereiraBiostatistics Department, Clinical Research and Innovation Department, University. Hospital Clermont-Ferrand, Clermont-Ferrand.
Anne TournadreRheumatology Department, CHU Clermont-Ferrand.
Roland ChapurlatService de rhumatologie et pathologie osseuse, Hôpital E.-Herriot, Lyon.

Funding

GRIO
6 · The paper itself

Abstract

BACKGROUND/

objectivesBone and cardiovascular health are interconnected, yet their relationship with endothelial function in postmenopausal osteoporosis remains insufficiently understood. This study aimed to investigate, in women with osteoporosis, the associations between endothelial function, assessed by flow-mediated dilation (FMD), bone turnover, and cardiovascular disease risk.

methodsThis cohort study included consecutive postmenopausal osteoporosis outpatients from the Rheumatology Department of Clermont-Ferrand University Hospital, France. FMD was measured at the brachial artery and values contextualized with age-matched healthy women's data reported in the literature. Associations between FMD and bone-related parameters (bone mineral density, bone markers, fracture history, and treatments), and Systematic Coronary Risk Evaluation (SCORE2/2-OP) were analyzed.

resultsA total of 111 postmenopausal women with osteoporosis (mean age 69.4 ± 7.9 y; mean FMD=3.14 ± 2.28%) were included. No significant associations were found between FMD and bone-related parameters. FMD was positively associated with prior bisphosphonate use ( r =0.270, p =0.007) and inversely associated with SCORE2/2-OP ( r =-0.212, p =0.035), particularly among younger participants. Overall, 49.5% of patients had high/very high SCORE2/2-OP, and 55% of those classified as low/intermediate SCORE2/2-OP exhibited low FMD values.

conclusionsMeasurement of the endothelial function in postmenopausal osteoporosis brings additional information to cardiovascular risk calculation, suggesting that factors beyond traditional cardiovascular risk determinants contribute to vascular impairment. In clinical practice, our findings support cautious cardiovascular follow-up even in osteoporotic patients with low cardiovascular risk and underline possible positive effects of bisphosphonates on endothelial function.

Indexed as

Cardiovascular DiseasesEndothelium, VascularOsteoporosis, PostmenopausalAgedBone DensityBrachial ArteryCohort StudiesDiphosphonatesFemaleFranceHeart Disease Risk FactorsHumansMiddle AgedRisk FactorsVasodilationDiphosphonatesbisphosphonatescardiovascularendothelial functionosteoporosis

Identifiers

PMID42257649
PMCPMC13387689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.